You are currently viewing Ketotifen and indomethacin combination treatment clinical trial for COVID-19 (KICC COVID-19)

Ketotifen and indomethacin combination treatment clinical trial for COVID-19 (KICC COVID-19)

Project Summary

The purpose of this study is to evaluate the safety and effectiveness of Ketotifen and Indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and Indomethacin are medications approved to treat diseases other than COVID-19.

Study Duration

Till target participants are met

Objectives

“To evaluate the safety of ketotifen fumarate and indomethacin, in combination, in COVID-19 patients. 2. To investigate the effectiveness of Ketotifen fumarate and Indomethacin for improving clinical measures of respiratory function and /or resolution of COVID-19 symptoms.”

Team Members

Principal Investigator(s): Prof. Dr. Rajeev Shrestha

Co-Principal Investigator(s): Dr. Ram Bahadur Gurung

Co-Investigator(s): Dr. Dipesh Tamrakar, Dr. Nirish Vaidya, Dr. Samita Adhikary, Dr. Shristi Jonchhe, Dr. Pranodan Poudel, Dr. Prabin Poudel, Mr. Surendra K Madhup

Project Coordinator: Dr. Samita Adhikary

Research Assistants: Sunita Shrestha, Pooja Tamang, Melina Thapa, Shishir Ranjitkar, Reena Kharbujha, Rasmi Koirala, Arati Kuikel

Collaborating Partners: Sen-Jam Pharmaceutical

For more detailed Information, Please contact:  rajeev.shrestha@kusms.edu.np/rmaleku@hotmail.com or dipesht@kusms.edu.np